Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 3.4% – Here’s What Happened

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s share price traded down 3.4% on Thursday . The stock traded as low as $9.22 and last traded at $9.22. 20,860 shares were traded during mid-day trading, a decline of 96% from the average session volume of 587,191 shares. The stock had previously closed at $9.54.

Analyst Ratings Changes

ATXS has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Oppenheimer lifted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Down 3.6 %

The company has a market cap of $519.19 million, a PE ratio of -4.40 and a beta of 0.67. The stock’s 50 day simple moving average is $10.54 and its two-hundred day simple moving average is $10.72.

Institutional Trading of Astria Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC grew its position in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. boosted its position in Astria Therapeutics by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after buying an additional 61,457 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after acquiring an additional 218,518 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in Astria Therapeutics by 15.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after purchasing an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.